International journal of cardiology · 2026
GLIflozins in the prevention of contrast AssocIated NEphropathy: The GLICINE registry.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Verdoia Monica, Zilio Filippo, Nardin Matteo, Leverone Marta, Paternoster Jari, Faraguna Aron, Barnoffi Emanuel, Lorusso Domenico, Ciliberti Gennaro, Piva Tommaso, Nicolini Elisa, Marini Marco, Dello Russo Antonio, Mollace Rocco, Gasparini Gaia, Miccichè Eligio, Bonmassari Roberto, Rognoni Andrea, Cao Davide, Ciliberti Giuseppe
Аннотация
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) have shown to improve cardiovascular and renal outcomes in patients with heart failure, diabetes mellitus and chronic kidney disease. However, despite these conditions being consistently associated with an increased risk of contrast-associated acute kidney injury (CA-AKI), the role of SGLT2-I in the prevention of post-contrast nephropathy remains unclear.
OBJECTIVES: The aim of the present study was to evaluate the impact of chronic therapy with SGLT2-I on the occurrence of CA-AKI in patients undergoing coronary angiography and/or percutaneous coronary intervention (PCI).
METHODS: Patients undergoing coronary procedures and chronically (≥ 7 days) treated with SGLT2-I were retrospectively identified and paired 1:1 with those not receiving gliflozins, via propensity score matching. The primary endpoint was the occurrence of CA-AKI within 72 h after contrast media exposure (KDIGO definition).
RESULTS: A total of 724 patients were included (362 treated with SGLT2-I and 362 controls), of whom 20.6% were females, 73.2% had diabetes mellitus and 22.9% presented with acute coronary syndrome. CA-AKI occurred in 70 patients (9.7%) overall, with a significantly lower rate of events in the SGLT2-I treated patients (6.4% vs 13.0%, OR = 0.46 95%CI 0.27-0.77, p = 0.003). This association with SGLT2-I remained significant at multivariable analysis (adjusted OR = 0.50, 95%CI 0.29-0.87, p = 0.014), after correction for residual baseline differences and according to the RIFLE and AKIN criteria.
CONCLUSION: This study shows that among unselected patients undergoing coronary angiography and/or PCI, the chronic use of SGLT2-I is associated with a significant reduction in the rate of CA-AKI, as compared with untreated patients.
OBJECTIVES: The aim of the present study was to evaluate the impact of chronic therapy with SGLT2-I on the occurrence of CA-AKI in patients undergoing coronary angiography and/or percutaneous coronary intervention (PCI).
METHODS: Patients undergoing coronary procedures and chronically (≥ 7 days) treated with SGLT2-I were retrospectively identified and paired 1:1 with those not receiving gliflozins, via propensity score matching. The primary endpoint was the occurrence of CA-AKI within 72 h after contrast media exposure (KDIGO definition).
RESULTS: A total of 724 patients were included (362 treated with SGLT2-I and 362 controls), of whom 20.6% were females, 73.2% had diabetes mellitus and 22.9% presented with acute coronary syndrome. CA-AKI occurred in 70 patients (9.7%) overall, with a significantly lower rate of events in the SGLT2-I treated patients (6.4% vs 13.0%, OR = 0.46 95%CI 0.27-0.77, p = 0.003). This association with SGLT2-I remained significant at multivariable analysis (adjusted OR = 0.50, 95%CI 0.29-0.87, p = 0.014), after correction for residual baseline differences and according to the RIFLE and AKIN criteria.
CONCLUSION: This study shows that among unselected patients undergoing coronary angiography and/or PCI, the chronic use of SGLT2-I is associated with a significant reduction in the rate of CA-AKI, as compared with untreated patients.